Katharine Hsu

Title: Katharine Hsu: Innovator in Immunology

Introduction

Katharine Hsu is a prominent inventor based in New York, NY, known for her significant contributions to the field of immunology. With a total of five patents to her name, she has made remarkable advancements in the understanding and application of killer immunoglobulin-like receptors (KIRs).

Latest Patents

Her latest patents include innovative methods and kits for typing KIR2DL alleles. These methods and compositions, such as primers and primer pairs, are essential for identifying KIR2DL1, KIR2DL2, and KIR2DL3 alleles. The disclosed compositions and methods are particularly useful in selecting the most appropriate donors for hematopoietic cell transplantation (HCT). Another notable patent involves anti-KIR3DL1 antibodies, which are designed to bind to inhibitory human KIRs. This patent provides antibody agents that specifically target KIR3DL1, also known as CD158e, along with related nucleic acids, vectors, and methods for utilizing these KIR-binding antibody agents.

Career Highlights

Katharine has worked with esteemed organizations such as Memorial Sloan Kettering Cancer Center and Eureka Therapeutics, Inc. Her work in these institutions has furthered research and development in cancer treatment and immunotherapy.

Collaborations

Throughout her career, Katharine has collaborated with notable colleagues, including Nai-Kong V Cheung and Su Yan. These partnerships have contributed to her innovative research and the advancement of immunological therapies.

Conclusion

Katharine Hsu's contributions to immunology through her patents and collaborations highlight her role as a leading inventor in the field. Her work continues to impact the selection of donors for HCT and the development of targeted therapies.